Evolva Holding SA (EVE.S)

EVE.S on Swiss Exchange

1.30CHF
19 Dec 2014
Price Change (% chg)

CHF0.01 (+0.78%)
Prev Close
CHF1.29
Open
CHF1.30
Day's High
CHF1.30
Day's Low
CHF1.26
Volume
2,678,383
Avg. Vol
1,246,319
52-wk High
CHF1.62
52-wk Low
CHF0.97

EVE.S

Chart for EVE.S

About

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Company’s nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The... (more)

Overall

Beta: 0.63
Market Cap (Mil.): CHF429.12
Shares Outstanding (Mil.): 327.57
Dividend: --
Yield (%): --

Financials

  EVE.S Industry Sector
P/E (TTM): -- 159.35 38.84
EPS (TTM): -0.08 -- --
ROI: -15.88 -0.82 18.26
ROE: -17.71 -1.98 19.12
Search Stocks

BRIEF-Evolva completes share sale related to Allylix acquisition

* Evolva completes share sale related to Allylix acquisition

22 Dec 2014

BRIEF-Evolva sells EV-035 series to Emergent Biosolutions

* Announced that Emergent Biosolutions Inc. has acquired Evolva's anti-bacterial programme, EV-035 series

17 Dec 2014

BRIEF-Evolva Holding completes acquisition of Allylix

* To acquire Allylix in return for an overall consideration of 46 million newly-issued Evolva shares (about 14.1 pct of Evolva post transaction) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

16 Dec 2014

BRIEF-Evolva Holding announces multi-product collaboration with Takasago

* Announces signing of a binding term sheet for an exclusive collaboration with Takasago International Corporation, Japan

11 Dec 2014

BRIEF-Evolva Holding to acquire Allylix

* Says has agreed to acquire San Diego-based Allylix, Inc., a privately held yeast fermentation company with a focus on high-value ingredients, in an all-stock transaction

18 Nov 2014

BRIEF-Evolva & Cargill announce publication of Stevia Reb M patent application

Aug 15 - Evolva Holding SA : *Evolva & Cargill announce publication of Stevia Reb M patent application * Source text for Eikon * Further company coverage

15 Aug 2014

BRIEF-US DTRA to fund preclinical work on Evolva's antibiotic GC-072

Aug 14 - Evolva Holding SA : * US DTRA to fund preclinical work on evolva's antibiotic gc-072 * Entered into contract with US DTRA for program gc-072: first oral antibiotic

14 Aug 2014

BRIEF-Evolva Holding announces acquisition of Prosarix Ltd.

Aug 4 - Evolva Holding SA : * Says announces ac quisition of Cambridge, UK based Prosarix Ltd., a leading

04 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Sadif Analytics Prime
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks